Innovative digital solution supporting sun protection and vitamin D synthesis by using satellite-based monitoring of solar radiation

Photochemical & Photobiological Sciences 2022 | King's College London, Medcin Clinical Research Center, siHealth, BASF

Abstract

Public health campaigns advise minimising UV radiation (UVR) exposure to prevent skin cancer and precancer, e.g. actinic keratosis (AK). A 3-day clinical field study, in Brazil, was performed to evaluate the mobile app Sun4Health® by siHealth Ltd. The app performs real-time monitoring of both erythemal and vitamin D-effective solar radiation doses using satellite data, enabling personalised recommendations on optimal sun exposure time and sunscreen use. When coupled to a wearable device, the app also provides body-site specific recommendations (“3D” version). 59 healthy volunteers were randomised into 3 groups, each given a different app providing: (1) ultraviolet index only (control app), (2) personalised recommendations and sun overexposure alerts (Sun4Health® app), (3) as (2) but connected via Bluetooth to a wearable device to monitor sun exposure in 3D (Sun4Health®-3D app). Participants were offered sunscreens (SPF 30 and 50) to use at their discretion. Erythema, quantified by reflectance spectroscopy, was assessed daily in the mornings and evenings on six body sites. Serum vitamin D (25(OH)D3) was measured before and after the study. Mean increase of erythema (Mexameter® units ± SD) of all exposed body sites combined over 3 days showed 55.76 ± 47.47 for group 1, 40.27 ± 37.91 for group 2 and 37.12 ± 30.69 for group 3 (p < 0.05 for all groups). Mean increase of serum 25(OH)D3 (nmol/l ± SD) showed 1.32 ± 36.49 for group 1, 6.38 ± 21.19 for group 2 and 18.68 ± 35.45 for group 3 (p > 0.05 for all groups). The results show that the Sun4Health® app is safe to use and can modify behaviour to reduce skin erythema (sunburn) yet not decreasing vitamin D status.

Authors

Antony R. Young*, Sérgio Schalka**, Rowan C. Temple***, Emilio Simeone***, Myriam Sohn****, Christina Kohlmann***** and Marco Morelli***

* St John’s Institute of Dermatology, King’s College London, London, UK

** Department of Dermatology, Medcin Clinical Research Center, Osasco, SP, Brazil

*** siHealth Ltd, Harwell Campus, Didcot, Oxfordshire, UK

**** BASF Grenzach GmbH, Grenzach-Wyhlen, Germany

***** BASF Personal Care and Nutrition GmbH, Düsseldorf, Germany

 

Corresponding Author: marco.morelli@sihealth.co.uk